Legal and General DTR Announc

Hikma Pharmaceuticals Plc
31 October 2007


                            
                   Notification of major interests in shares


LONDON, 31 October 2007 - Hikma Pharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX:
HIK), the multinational pharmaceuticals group, announces as follows:

 1   Identity of the issuer or the underlying issuer of existing    Hikma Pharmaceuticals PLC
     shares to which the voting rights are attached              
                                                                 

 2   Reason for the notification                                            Yes/no

     An acquisition or disposal of voting rights                            Yes

     An acquisition or disposal of financial instruments which may result
     in the acquisition of shares already issues to which voting rights are
     attached

     An event changing the breakdown of voting rights

     Other (please specify): Compliance with the Transparency Directive


 3   Full name of the person subject to the notification    Legal & General Group Plc (L&G)
     obligation                                             

 4   Full name of shareholders if different from above      -

 5   Date of the Transaction (and date on which the         17 October 2007
     threshold crossed is reached differently)

 6   Date on which the issuer notified                      31 October 2007

 7   Threshold that is crossed                              3%

 8   Notified details

A. Voting rights attached to shares

Class      Situation     Resulting situation after the triggering transaction
type of    previous to
shares     the
(if        triggering
possible   transaction
using      Number   Number   Number of shares      Number of voting      % of voting
the ISIN   of       of                             rights                rights
code)      shares   voting
                    rights   Direct    Indirect    Direct    Indirect    Direct  Indirect

Ordinary   Below    Below    5,181,598             5,181,598             3.04%
Shares     3%       3%

B. Financial instruments
Resulting situation after the triggering transaction
Type of      Expiration Exercise/     Number of voting rights that may   % of
financial    Date       Conversion    be acquired if the instrument if   voting
instrument              Period/Date   exercised/converted                rights


Total A+B

Number of Voting rights                  % of voting rights
                                 
5,181,598                                3.04%

 9   Chain of controlled undertakings through which the voting rights and/or the financial
     instruments are effectively held, if applicable

     Legal & General Group Plc (Direct and Indirect) (Group)

     Legal & General Investment Management (Holdings) Limited
     (LGIMH) (Direct and Indirect)

     Legal & General Investment Management Limited (Indirect)
     (LGIM)

         Legal & General Group Plc (Direct) (L&G) (5,181,598 - 3.04% = LGAS, LGPL & PMC)

     Legal & General Investment Management         Legal & General Insurance Holdings Limited
     (Holdings) Limited (Direct) (LGIMHD)          (Direct) (LGIH)

     Legal & General Assurance (Pensions           Legal & General Assurance Society Limited
     Management) Limited (PMC)                     (LGAS & LGPL)

                                                   Legal & General Pensions Limited (Direct)
                                                   (LGPL)

Proxy Voting

   10   Name of the proxy holder                                           N/A

   11   Number of voting rights proxy holder will cease to hold            N/A

   12   Date on which proxy holder will cease to hold voting rights        N/A



Additional Information      Notification using the total voting rights figure of
                            170,273,007
                            Please note this notification has been delayed due 
                            to the large number of disclosures required 
                            following a substantial amount of new business which 
                            has come to us in the form of an in-specie transfer.

 13   Contact name          Helen Lewis (LGIM)
      

 14   Contact telephone     [phone]
      number





                                    - ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Henry Knowles               [phone]
Company Secretary

About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2006, the Group
had revenue of $317 million and profit attributable to shareholders of $54.5
million. For news and other information, please visit www.hikma.com.






                      This information is provided by RNS
            The company news service from the London Stock Exchange